A prospective, randomized pilot trial of perfluorocarbon-induced lung growth in newborns with congenital diaphragmatic hernia

Ronald B. Hirschl, William Fox, Philip L. Glick, Jay Greenspan, Kendra Smith, Anne Thompson, Jay Wilson, N. Scott Adzick, D. C. Stolar, Max Langham

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Background/Purpose: Initial laboratory and clinical data suggest that partial liquid ventilation (PLV) can enhance pulmonary function and that lung growth can be induced via distension of the newborn lung using perfluorocarbon in patients with congenital diaphragmatic hernia (CDH). The authors, therefore, performed a prospective, randomized pilot study evaluating PLV and perfluorocarbon-induced lung growth (PILG) in newborns with CDH on extracorporeal life support (ECLS) at 6 medical centers. Methods: Patients were selected randomly using a permuted block design to PLV/PILG (n = 8) or conventional mechanical ventilation (CMV/control, n = 5). Patients in the PILG group received daily doses which filled the lungs with perflubron for up to 7 days and were placed on continuous positive airway pressure of 5 to 8 cm H 2 O. CMV patients were treated with standard mechanical ventilation while on extracorporeal membrane oxygenation (ECMO). Results: A total of 13 patients were evaluated in this study. All 3 patients enrolled without being on ECLS rapidly transitioned to ECLS. The study, therefore, effectively evaluated PILG (n = 8) versus standard ventilation (control, n = 5) on ECLS. Mean (± SE) gestational age was 37 ± 1 weeks and weight was 3.1 ± 0.1 kg. Time on ECMO was 9.8 ± 2.3 days in the PILG and 14.5 ± 3.5 days (P = .58) in the control group. Survival rate in the PILG group was 6 of 8 (75%), whereas survival rate was 2 of 5 (40%) in the control group (P = .50). The number of days free from the ventilator in the first 28 days (VFD) was 6.3 ± 3.3 days with PILG and 4.6 ± 4.6 days with control (P = .9). Causes of death in the PILG group included sepsis and renal failure in one patient and pulmonary hypertension in the other. There were no safety issues, and the deaths in the PILG group did not appear to be related to the administration of perflubron. Conclusions: These data show that PILG can be performed safely. The survival rate, VFD, and time on ECMO data, although not conclusive, are encouraging and indicate the need for a definitive trial of this novel intervention in these neonates with high mortality.

Original languageEnglish (US)
Pages (from-to)283-289
Number of pages7
JournalJournal of Pediatric Surgery
Volume38
Issue number3
DOIs
StatePublished - Mar 1 2003
Externally publishedYes

Fingerprint

Fluorocarbons
Newborn Infant
Lung
Extracorporeal Membrane Oxygenation
Growth
Liquid Ventilation
Survival Rate
Mechanical Ventilators
Congenital Diaphragmatic Hernias
Artificial Respiration
Control Groups
Continuous Positive Airway Pressure
Pulmonary Hypertension
Gestational Age

All Science Journal Classification (ASJC) codes

  • Surgery
  • Pediatrics, Perinatology, and Child Health

Cite this

A prospective, randomized pilot trial of perfluorocarbon-induced lung growth in newborns with congenital diaphragmatic hernia. / Hirschl, Ronald B.; Fox, William; Glick, Philip L.; Greenspan, Jay; Smith, Kendra; Thompson, Anne; Wilson, Jay; Adzick, N. Scott; Stolar, D. C.; Langham, Max.

In: Journal of Pediatric Surgery, Vol. 38, No. 3, 01.03.2003, p. 283-289.

Research output: Contribution to journalArticle

Hirschl, RB, Fox, W, Glick, PL, Greenspan, J, Smith, K, Thompson, A, Wilson, J, Adzick, NS, Stolar, DC & Langham, M 2003, 'A prospective, randomized pilot trial of perfluorocarbon-induced lung growth in newborns with congenital diaphragmatic hernia', Journal of Pediatric Surgery, vol. 38, no. 3, pp. 283-289. https://doi.org/10.1053/jpsu.2003.50095
Hirschl, Ronald B. ; Fox, William ; Glick, Philip L. ; Greenspan, Jay ; Smith, Kendra ; Thompson, Anne ; Wilson, Jay ; Adzick, N. Scott ; Stolar, D. C. ; Langham, Max. / A prospective, randomized pilot trial of perfluorocarbon-induced lung growth in newborns with congenital diaphragmatic hernia. In: Journal of Pediatric Surgery. 2003 ; Vol. 38, No. 3. pp. 283-289.
@article{f1e8e088f88b469598db025ffaab2dd8,
title = "A prospective, randomized pilot trial of perfluorocarbon-induced lung growth in newborns with congenital diaphragmatic hernia",
abstract = "Background/Purpose: Initial laboratory and clinical data suggest that partial liquid ventilation (PLV) can enhance pulmonary function and that lung growth can be induced via distension of the newborn lung using perfluorocarbon in patients with congenital diaphragmatic hernia (CDH). The authors, therefore, performed a prospective, randomized pilot study evaluating PLV and perfluorocarbon-induced lung growth (PILG) in newborns with CDH on extracorporeal life support (ECLS) at 6 medical centers. Methods: Patients were selected randomly using a permuted block design to PLV/PILG (n = 8) or conventional mechanical ventilation (CMV/control, n = 5). Patients in the PILG group received daily doses which filled the lungs with perflubron for up to 7 days and were placed on continuous positive airway pressure of 5 to 8 cm H 2 O. CMV patients were treated with standard mechanical ventilation while on extracorporeal membrane oxygenation (ECMO). Results: A total of 13 patients were evaluated in this study. All 3 patients enrolled without being on ECLS rapidly transitioned to ECLS. The study, therefore, effectively evaluated PILG (n = 8) versus standard ventilation (control, n = 5) on ECLS. Mean (± SE) gestational age was 37 ± 1 weeks and weight was 3.1 ± 0.1 kg. Time on ECMO was 9.8 ± 2.3 days in the PILG and 14.5 ± 3.5 days (P = .58) in the control group. Survival rate in the PILG group was 6 of 8 (75{\%}), whereas survival rate was 2 of 5 (40{\%}) in the control group (P = .50). The number of days free from the ventilator in the first 28 days (VFD) was 6.3 ± 3.3 days with PILG and 4.6 ± 4.6 days with control (P = .9). Causes of death in the PILG group included sepsis and renal failure in one patient and pulmonary hypertension in the other. There were no safety issues, and the deaths in the PILG group did not appear to be related to the administration of perflubron. Conclusions: These data show that PILG can be performed safely. The survival rate, VFD, and time on ECMO data, although not conclusive, are encouraging and indicate the need for a definitive trial of this novel intervention in these neonates with high mortality.",
author = "Hirschl, {Ronald B.} and William Fox and Glick, {Philip L.} and Jay Greenspan and Kendra Smith and Anne Thompson and Jay Wilson and Adzick, {N. Scott} and Stolar, {D. C.} and Max Langham",
year = "2003",
month = "3",
day = "1",
doi = "10.1053/jpsu.2003.50095",
language = "English (US)",
volume = "38",
pages = "283--289",
journal = "Journal of Pediatric Surgery",
issn = "0022-3468",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - A prospective, randomized pilot trial of perfluorocarbon-induced lung growth in newborns with congenital diaphragmatic hernia

AU - Hirschl, Ronald B.

AU - Fox, William

AU - Glick, Philip L.

AU - Greenspan, Jay

AU - Smith, Kendra

AU - Thompson, Anne

AU - Wilson, Jay

AU - Adzick, N. Scott

AU - Stolar, D. C.

AU - Langham, Max

PY - 2003/3/1

Y1 - 2003/3/1

N2 - Background/Purpose: Initial laboratory and clinical data suggest that partial liquid ventilation (PLV) can enhance pulmonary function and that lung growth can be induced via distension of the newborn lung using perfluorocarbon in patients with congenital diaphragmatic hernia (CDH). The authors, therefore, performed a prospective, randomized pilot study evaluating PLV and perfluorocarbon-induced lung growth (PILG) in newborns with CDH on extracorporeal life support (ECLS) at 6 medical centers. Methods: Patients were selected randomly using a permuted block design to PLV/PILG (n = 8) or conventional mechanical ventilation (CMV/control, n = 5). Patients in the PILG group received daily doses which filled the lungs with perflubron for up to 7 days and were placed on continuous positive airway pressure of 5 to 8 cm H 2 O. CMV patients were treated with standard mechanical ventilation while on extracorporeal membrane oxygenation (ECMO). Results: A total of 13 patients were evaluated in this study. All 3 patients enrolled without being on ECLS rapidly transitioned to ECLS. The study, therefore, effectively evaluated PILG (n = 8) versus standard ventilation (control, n = 5) on ECLS. Mean (± SE) gestational age was 37 ± 1 weeks and weight was 3.1 ± 0.1 kg. Time on ECMO was 9.8 ± 2.3 days in the PILG and 14.5 ± 3.5 days (P = .58) in the control group. Survival rate in the PILG group was 6 of 8 (75%), whereas survival rate was 2 of 5 (40%) in the control group (P = .50). The number of days free from the ventilator in the first 28 days (VFD) was 6.3 ± 3.3 days with PILG and 4.6 ± 4.6 days with control (P = .9). Causes of death in the PILG group included sepsis and renal failure in one patient and pulmonary hypertension in the other. There were no safety issues, and the deaths in the PILG group did not appear to be related to the administration of perflubron. Conclusions: These data show that PILG can be performed safely. The survival rate, VFD, and time on ECMO data, although not conclusive, are encouraging and indicate the need for a definitive trial of this novel intervention in these neonates with high mortality.

AB - Background/Purpose: Initial laboratory and clinical data suggest that partial liquid ventilation (PLV) can enhance pulmonary function and that lung growth can be induced via distension of the newborn lung using perfluorocarbon in patients with congenital diaphragmatic hernia (CDH). The authors, therefore, performed a prospective, randomized pilot study evaluating PLV and perfluorocarbon-induced lung growth (PILG) in newborns with CDH on extracorporeal life support (ECLS) at 6 medical centers. Methods: Patients were selected randomly using a permuted block design to PLV/PILG (n = 8) or conventional mechanical ventilation (CMV/control, n = 5). Patients in the PILG group received daily doses which filled the lungs with perflubron for up to 7 days and were placed on continuous positive airway pressure of 5 to 8 cm H 2 O. CMV patients were treated with standard mechanical ventilation while on extracorporeal membrane oxygenation (ECMO). Results: A total of 13 patients were evaluated in this study. All 3 patients enrolled without being on ECLS rapidly transitioned to ECLS. The study, therefore, effectively evaluated PILG (n = 8) versus standard ventilation (control, n = 5) on ECLS. Mean (± SE) gestational age was 37 ± 1 weeks and weight was 3.1 ± 0.1 kg. Time on ECMO was 9.8 ± 2.3 days in the PILG and 14.5 ± 3.5 days (P = .58) in the control group. Survival rate in the PILG group was 6 of 8 (75%), whereas survival rate was 2 of 5 (40%) in the control group (P = .50). The number of days free from the ventilator in the first 28 days (VFD) was 6.3 ± 3.3 days with PILG and 4.6 ± 4.6 days with control (P = .9). Causes of death in the PILG group included sepsis and renal failure in one patient and pulmonary hypertension in the other. There were no safety issues, and the deaths in the PILG group did not appear to be related to the administration of perflubron. Conclusions: These data show that PILG can be performed safely. The survival rate, VFD, and time on ECMO data, although not conclusive, are encouraging and indicate the need for a definitive trial of this novel intervention in these neonates with high mortality.

UR - http://www.scopus.com/inward/record.url?scp=0037372102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037372102&partnerID=8YFLogxK

U2 - 10.1053/jpsu.2003.50095

DO - 10.1053/jpsu.2003.50095

M3 - Article

VL - 38

SP - 283

EP - 289

JO - Journal of Pediatric Surgery

JF - Journal of Pediatric Surgery

SN - 0022-3468

IS - 3

ER -